Jesper J. Lange’s Post

View profile for Jesper J. Lange, graphic

CEO MC2 Therapeutics

2024 is set to be a pivotal year for MC2 Therapeutics with significant milestones in our three Phase 2 stage clinical programs within Immunology and Inflammation. Next week in San Francisco, I am representing our dedicated MC2 Therapeutics team at the J.P. Morgan Healthcare Conference to provide an update on our progress and plans and to discuss collaborations with investors and industry partners.   Our two novel drug candidates (an oral HSP90 Inhibitor and a topical Iso-cyanate scavenger) are first-in-class with new mode of action and multiple indications potential, including Hidradenitis Suppurativa, CKD-associated Pruritus (CKD-aP) and Vulvar Lichen Sclerosus. Addressing the unmet needs of millions of patients and a testament to our commitment to pioneer novel treatment paradigms within I&I.   I look forward to engaging.   #JPM2024 #HealthcareInnovation #MC2Therapeutics #ClinicalAdvancement #Networking  

  • No alternative text description for this image
Morten Faester

LifeScience Business Development & Licensing at Pharmacosmos

10mo

See you there…Safe travels, assume we’ll be on the same SK flight CPH/SFO on Sunday 😃

Like
Reply

To view or add a comment, sign in

Explore topics